FDA NOMINATION HEARING DRIVES THE WEEK IN HEALTH POLICY
President Trump’s nominee to lead the Food and Drug Administration, Dr. Stephen Hahn, will appear Wednesday before the Senate Health, Education, Labor and Pensions Committee for a hearing on his nomination.
Hahn, an oncologist and chief medical executive at MD Anderson Cancer Center in Houston, is seen by lawmakers as a blank slate – he has a strong resume as a physician but scant policy experience. However, HELP Chairman Lamar Alexander, R-Tenn., announced he supports Hahn after meeting with the nominee Nov. 6. Meanwhile, Democrats are eager to replace current acting FDA Commissioner Brett Giroir because of concerns over his positions on social issues like abortion.
Still, Hahn is sure to face wide-ranging questions from lawmakers about the mission of the agency he hopes to lead. Senators are also likely to seek commitments from him to focus on certain policy issues.
Given Hahn’s lack of policy track record, senators will want details of his views on regulation of food, drugs and medical devices. Hahn can expect lawmakers to press him on ways the FDA can help to lower prescription drug costs while protecting medical innovation, including Trump’s efforts to allow drug importation. E-cigarettes will be a hot topic, as will cannabis regulation and efforts to stem opioid abuse.
PRESSURE FROM WHITE HOUSE ON DRUG PRICING
Despite bipartisan and bicameral interest, legislation to address prescription drug costs has faced continued delays as lawmakers await budget estimates and struggle with disagreements on policy specifics. President Donald Trump and his deputies are continuing to press the Hill for action.
According to reports from the Associated Press, Trump’s top domestic policy advisor, Joe Grogan, said recently the administration is continuing to press senators to support bipartisan legislation passed by the Finance Committee that would cap seniors’ out-of-pocket costs and require rebates from drugmakers if prices increase faster than inflation. But Grogan also acknowledged the “current complications” including policy disagreements – as well as impeachment consuming the political environment.
Health and Human Services Secretary Alex Azar and other officials have held multiple meetings with Republican lawmakers across the Hill to try to drive support for the Senate bill.
Yet broad legislation on the issue remains a long shot to reach Trump’s desk. Though Trump previously voiced support for direct government negotiation on drug prices, the administration does not support House Democrats’ bill to implement negotiation, currently scheduled for a vote next month.
The White House views Christmas as an effective deadline on getting drug pricing legislation done because the Senate could be consumed by impeachment considerations in January and even into February. Yet December’s legislative calendar will also be crowded by must-pass items, as lawmakers are set this week to pass a short-term government funding extension to Dec. 20.
Despite the administration’s pressure, most stakeholders are skeptical that lawmakers will be able to thread a needle this year with broad drug pricing legislation that can pass the Republican Senate and Democratic House. Continue Reading